PREMARIN-0.625 0.625MG/G VAGINAL CREAM

Indications

• Menopausal symptoms
• Vulvar and vaginal atrophy
• Prevention of osteoporosis in postmenopausal women
• Hypoestrogenism due to hypogonadism or castration

Dosage

Children: Conjugated estrogens are not typically indicated for use in the pediatric population. Refer to specialized resources for any off-label use.

Adults: Refer to the BNF for specific dosing guidelines, as doses may vary based on the indication and patient-specific factors.

Mechanism of action

Conjugated estrogens exert their effects primarily through binding to estrogen receptors, leading to the activation of estrogen-responsive genes. This binding triggers a cascade of biological responses that promote the development and maintenance of female reproductive tissues, regulation of the menstrual cycle, and other systemic effects such as bone density maintenance and modulation of cholesterol levels.

Pharmacodynamics

The pharmacodynamics of conjugated estrogens involve their role in modulating gene expression within estrogen-responsive tissues. They help to alleviate symptoms associated with menopause, such as hot flashes and vaginal dryness, and play a critical role in bone health by inhibiting osteoclast activity, thus reducing bone resorption and helping to prevent osteoporosis.

Pharmacokinetics

Following oral administration, conjugated estrogens are absorbed through the gastrointestinal tract. They undergo first-pass metabolism in the liver, which can affect their bioavailability. The half-life of conjugated estrogens varies, but they generally have a half-life of several hours. They are metabolized primarily in the liver and excreted in urine. The pharmacokinetics can be influenced by factors such as age, liver function, and concurrent medications.

Contra-indications

• Known hypersensitivity to conjugated estrogens or any of the excipients
• Estrogen-dependent neoplasms, including breast cancer
• Undiagnosed abnormal genital bleeding
• Active or past venous thromboembolic disorders
• Severe liver dysfunction or disease
• Pregnancy

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Abdominal cramps
• Bloating
• Mood changes
• Increased risk of thromboembolic events
• Hypertension
• Cholestatic jaundice
• Gallbladder disease

Interactions

• Anticoagulants may have altered effects
• Certain anticonvulsants may reduce efficacy of estrogen therapy
• Rifampicin and other enzyme inducers may decrease effectiveness
• St. John's Wort may decrease hormone levels

Precautions

• Monitor patients for signs of thromboembolic disorders
• Assess risk factors for cardiovascular disease
• Evaluate liver function before and during treatment
• Consider individual patient history of breast cancer or other estrogen-sensitive conditions

Pregnancy

Conjugated estrogens are contraindicated in pregnancy due to risk of fetal harm.

Breast-feeding

Conjugated estrogens may be excreted in breast milk; use with caution in breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable forms

Indications

• Menopausal symptoms (e.g., hot flashes, night sweats)
• Hormone replacement therapy
• Contraception
• Hypogonadism in females
• Osteoporosis prevention
• Certain hormone-sensitive cancers (e.g., breast cancer)
• Irregular menstrual cycles
• Premature ovarian insufficiency

Dosage

Children: Dosage is dependent on the indication, age, and weight. Refer to the BNF for Children for specific recommendations.

Adults: Dosage varies based on indication and formulation. Refer to specific prescribing guidelines.

Mechanism of action

Oestrogens exert their effects primarily through binding to oestrogen receptors (ER), which are nuclear hormone receptors. Upon binding, the oestrogen-receptor complex translocates to the nucleus and regulates gene expression, influencing the synthesis of proteins that affect cell growth, differentiation, and metabolism. This action is pivotal in reproductive tissues, breast tissue, and other target organs.

Pharmacodynamics

The pharmacodynamic effects of oestrogens include modulation of the menstrual cycle, promotion of endometrial proliferation, enhancement of bone mineral density, and regulation of lipid metabolism. Oestrogens also influence the function of various tissues, including the cardiovascular system and the central nervous system, contributing to mood regulation and cognitive function.

Pharmacokinetics

Oestrogens are absorbed from the gastrointestinal tract and undergo extensive first-pass metabolism in the liver. They are primarily metabolized by cytochrome P450 enzymes. Oestrogens have a half-life that varies depending on the specific compound, and they are excreted primarily through urine. Their bioavailability can be affected by factors such as route of administration and formulation.

Contra-indications

• History of thromboembolic disorders
• Known or suspected breast cancer
• Estrogen-dependent neoplasia
• Undiagnosed vaginal bleeding
• Severe liver disease
• Pregnancy

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Weight gain
• Mood changes
• Increased risk of thromboembolic events
• Hypertension

Interactions

• Anticonvulsants (e.g., phenytoin, carbamazepine) may reduce estrogen effectiveness
• Antibiotics (e.g., rifampicin) can decrease estrogen levels
• Warfarin may have altered effects when combined with estrogen
• Corticosteroids may have increased effects

Precautions

• Monitor for signs of thromboembolism
• Use with caution in patients with a history of migraines
• Assess liver function prior to initiation
• Regular breast examinations and mammograms are recommended

Pregnancy

Oestrogen is contraindicated in pregnancy due to potential harm to the fetus.

Breast-feeding

Use with caution, as oestrogen can affect milk production and composition.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Transdermal patches
• Injectable forms
• Topical creams or gels